KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Other financing activities (2017 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Other financing activities for 9 consecutive years, with $40.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other financing activities rose 263.64% year-over-year to $40.0 million, compared with a TTM value of $41.0 million through Dec 2025, up 612.5%, and an annual FY2025 reading of $41.0 million, up 612.5% over the prior year.
  • Other financing activities was $40.0 million for Q4 2025 at Teva Pharmaceutical Industries, up from -$2.0 million in the prior quarter.
  • Across five years, Other financing activities topped out at $40.0 million in Q4 2025 and bottomed at -$76.0 million in Q3 2023.
  • Average Other financing activities over 5 years is -$16.8 million, with a median of -$2.5 million recorded in 2021.
  • The sharpest move saw Other financing activities crashed 4100.0% in 2022, then skyrocketed 263.64% in 2025.
  • Year by year, Other financing activities stood at -$1.0 million in 2021, then tumbled by 200.0% to -$3.0 million in 2022, then tumbled by 2433.33% to -$76.0 million in 2023, then skyrocketed by 114.47% to $11.0 million in 2024, then surged by 263.64% to $40.0 million in 2025.
  • Business Quant data shows Other financing activities for TEVA at $40.0 million in Q4 2025, -$2.0 million in Q3 2025, and $3.0 million in Q1 2025.